The purpose of this review is to comprehensively examine the various therapeutic agents available to treat autoimmune eye disease, their indications, clinical safety and recent developments. The stepladder approach is reviewed, including corticosteroid administration of various forms, classic immunomodulators, and newer biologic response modifiers. The authors present that corticosteroid monotherapy is almost never curative and carries significant side effects, while immunomodulatory therapy, when used appropriately as way to induce steroid-free remission, carries far less risk of causing longterm complications and provides greater potential of altering the immune system to induce a durable remission.
INTRODUCTION
Uveitis is the third leading cause of preventable blindness in the United States. Vision loss from uveitis can be secondary to cystoid macular edema, glaucoma, cataract, retinal vasculature abnormalities, corneal opacities, optic nerve atrophy, retinal and macular lesions. New modalities and effective therapies to control ocular inflammatory disease have been developed. The goal of therapy is to suppress the immune inflammatory response in order to preserve the integrity of the eye and therefore preserve visual function. The choice of agent is based on the patient's underlying disease, age, sex, medical conditions, and risk factors. The patient is monitored closely to assess the response and to screen for adverse effects.
Therapy is continued with the mission to
Electronic supplementary material The online version of this article (doi:10.1007/s40123-014-0023-x) contains supplementary material, which is available to authorized users. achieve quiescence of inflammation for a period of 2 years prior to considering tapering or discontinuation. This review will focus on the various therapeutic agents available to treat autoimmune eye disease, its indications, clinical safety and recent developments.
DISCUSSION

Corticosteroids
Corticosteroids therapy has been used extensively in the treatment of non-infectious uveitis. It can be administered in the form of topical drops, intravitreal and periocular injections, intravitreal implants and systemically which will be described [1] .
Corticosteroids (mineralocorticoids and glucocorticoids) are naturally produced in response to adrenocorticotropic hormone (ACTH)-induced conversion of cholesterol to pregnolone in the adrenal cortex.
Glucocorticoids regulate gluconeogenesis and inhibit the inflammatory response. On the other hand, mineralocorticoids regulate the body's ion balance by controlling inorganic ion reabsorption by the kidney. Corticosteroids are composed of 21 carbon molecules consisting of three hexane rings, one pentane ring and cyclopentanoperhydrophenanthrene nucleus [2] . Changes in this basic structure gives rise to different compounds with different biologic properties such as anti-inflammatory activity, duration of action, trans-corneal penetration, sodium retaining activity, efficacy and side effect profile [2] .
The mechanism of corticosteroids has a direct impact on protein synthesis at the cellular level by switching gene transcription on and off. Corticosteroid receptors have been isolated in the ciliary body, corneoscleral tissue and iris. Glucocorticoids inhibit vascular permeability and vasodilation thereby affecting leukocyte migration to sites of inflammation and leukocyte distribution and survival. In addition, the distribution and maturation of lymphocytes in the thymus is also affected leading to lymphocytopenia.
Long-term high doses may affect B lymphocytes and antibody production while small and moderate doses have an impact on T lymphocytes [2] . acid. The end result is inhibition of prostaglandin production through the cyclooxygenase pathway and inhibition in production of leukotrienes through the lipooxygenase pathway [2] .
Topical Corticosteroids
Topical corticosteroids are frequently employed as the initial therapy for uveitis, specifically for anterior uveitis. The drops can be easily administered by the patient and frequency of dosing can be modified and tapered based on the degree of inflammation. There is wide variety of topical steroids available in the market with a range of anti-inflammatory activity. The most commonly prescribed is prednisolone acetate 1%, which is adequate for most cases of uncomplicated anterior uveitis. Less potent options include loteprednol and rimexolone that can be used when there is a concern about elevated intraocular pressure [3] . However, these agents may not be adequate for Immunosuppressive Therapy for Eye Diseases (SITE) multi-center retrospective cohort study of 384 patients treated with methotrexate as the only immunosuppressant for ocular inflammation showed that 66% of patients were able to achieve quiescence of their ocular inflammation within a year, also permitting a taper of systemic steroids [5] . Methotrexate was employed in controlling anterior uveitis, posterior uveitis, panuveitis and mucous membrane pemphigoid. Therapy success was most commonly achieved in patients with anterior uveitis and scleritis. Methotrexate has a long track record and has been safely and efficiently used in the adult as well as in the pediatric population. It is available in the oral, subcutaneous and intravenous administration.
It is provided in doses of 7.5 mg and up to 25 mg once a week. Folic acid (1 mg) daily is also employed to limit side effects due to folate deficiency. It takes about 3-6 weeks for methotrexate to become effective. Side effects may include bone marrow suppression, elevated liver enzymes, fatigue, malaise, gastrointestinal discomfort. These side effects are typically reversible with dose reduction or by stopping the medication. The subcutaneous route can be more effective in the same doses without affecting its tolerability. Therapy is continued for 2 years after quiescence is achieved to be able to obtain durable remission. If no adequate control is achieved, the dose can be increased by 5 mg per week. If no improvement is noted another agent can be added or methotrexate needs to be replaced. Important laboratory testing to follow include complete blood counts (CBC), liver enzymes (LFT) and creatinine at 6-week intervals to assess for any kind of toxicity [5] .
Mycophenolate Mofetil
Mycophenolate mofetil (MMF) inhibits inosine monophosphate dehydrogenase causing a reduction of nucleotides required for purine synthesis, DNA synthesis and for B-and T-cell proliferation. It also interferes with cell adhesion on vascular endothelium, lymphocytic chemotaxis and decreases antibody synthesis [5] .
Mycophenolate has been successfully employed as monotherapy or in conjunction with steroids, cyclosporine, azathioprine and methotrexate to treat ocular inflammation [12] . It can also be the next agent to be employed if a patient does not tolerate methotrexate. In the SITE cohort study which included 236 patients with ocular inflammatory disease, 73% of them were able to achieve inflammation control within 1 year, while 55% of patients were able to experience a steroid-sparing effect at the 1 year mark [13] .
Side effects led to the discontinuation of MMF in 12% of patients during the first year. The SITE study also showed no increase in overall or cancer-related mortality in patients who were treated with MMF when compared to untreated controls [11, 14] .
The starting dose of MMF is 500 mg twice a day by oral route on an empty stomach, 1 h prior to eating or 2 h after meals while assessing for side effects. If the patient is tolerating the medication well, the dose can be increased to 1 g twice a day with a maximum dose of 3 g a day.
The most common side effect is gastrointestinal irritability, followed by bone marrow suppression and elevated liver function tests.
Baseline laboratory testing such as CBC with differential, liver function tests are done at the onset of therapy and then monitored every 4-6 weeks. Duration of therapy is usually 2 years in order to achieve steroid-free remission.
Azathioprine
Azathioprine is a prodrug that it is metabolized in the liver to the active form, 12 inhibiting the mTOR pathway and activation of p70 kinase, stopping the cell cycle between G1 and S phases which prevents the activation and proliferation of T lymphocytes [1, 11] . It has also been shown to block the growth factor proliferation signaling and activation of hypoxia inducible factor (HIF)-1a.
Sirolimus was shown to be an effective strategy in reducing inflammation [19] . cystitis, and hematuria were the most common toxicities noted that led to discontinuation of therapy in 3% of patients during the first year.
Opportunistic infections caused therapy cessation in 3% of patients during the first year, including Pneumocystis carinii pneumonia, that lead to the death of one patient, managed using the commonly accepted guidelines, but who did not take the pneumocystis prophylaxis. In 9.7% of patients, therapy was discontinued due to inadequate inflammation control [11, 27] . The SITE study showed no significant increase in overall mortality. The data suggested a possible increased risk of cancer mortality with cyclophosphamide use, but additional data are required since the results were not conclusive [14] .
Oral cyclophosphamide is dosed at 1-3 mg/ kg/day. Intravenous pulsed therapy dosing and timing is titrated to achieve a white blood cell count of 3,000-4,500 with an absolute neutrophil count C1,000. A recent study showed that pulsed IV cyclophosphamide results in high rate of sustained complete remission in patients with recalcitrant and fulminant, vision-threatening ocular inflammatory disease. Its side effect profile was excellent under the management of experienced clinicians and its use allowed tapering and discontinuation of corticosteroids [28] .
Chlorambucil
Chlorambucil is nitrogen mustard that replaces hydrogen ions with alkyl groups on DNA bases.
It causes intra-strand cross-linking and DNA to protein cross-linking, disrupting DNA replication, transcription and function. The SITE study showed no significant increase in overall mortality in patients treated with alkylating agents. A non-significant increase in cancer-related mortality was observed.
Chlorambucil has not been as extensively studied as cyclophosphamide. It was studied in Behcet's disease where high-dose, short-term therapy was effective in preventing recurrence after 6-24 months of use [1, 29] . It has also been used effectively in non-infectious uveitis related to human leukocyte antigen (HLA)-B27, JIA, pars planitis, sympathetic ophthalmia, and Crohn's disease.
Baseline CBC with differential and liver function tests are obtained prior to starting therapy. Close monitoring for side effects and myelosuppression should be done. Treatment parameters of white blood cell count of 3,000-4,500 with an absolute neutrophil count C1,000 should guide therapy. It can be started at an oral dose of 0.1 mg/kg/day, titrating the dose to clinical response and tolerance every 3 weeks with a maximum daily dose of 6-12 mg/day followed by a progressive reduction of the dose over the next 3-6 months. Treatment is continued for 1 year of disease quiescence to induce durable remission [11] . An alternate approach is short-term and high-dose therapy for 3-6 months. The initial dose is of 2 mg a day for 1 week, followed by an increase of 2 mg/day each week until inflammation is completely resolved or until the leukocyte count decreases to below 2,400 cells/ll or platelet count is below 100,000 cells/ll. CBC with differential is done weekly as the dose is being adjusted. Therapy is discontinued if bone marrow toxicity occurs [11] . A combination of the two approaches can be employed.
Biologic Response Modifiers
These agents specifically target cytokines or their inflammatory signaling pathways. They have revolutionized the treatment of inflammatory disease and offer novel options in the management of uveitis.
Etanercept
Etanercept is a soluble, bivalent receptor for tumor necrosis factor alpha (TNF-a). It competitively binds TNF-a and TNF-b inhibiting the immune activities that rely on these cytokines for signal transduction such as expression of adhesion molecules responsible for leukocyte migration and decreased synthesis of pro-inflammatory cytokines and matrix metalloproteinase (MMP). Etanercept has been effective in the treatment of arthritis, but its effect in uveitis is debatable [11, 30] . In a study, etanercept showed no significant efficacy over placebo in uveitis relapses in patients being tapered off methotrexate [31] . While other studies showed some improvement with etanercept in Behcet's associated uveitis and pediatric patients [32] . The SITE study, showed an increased risk of mortality and cancer-related mortality in patients taking TNF inhibitors, including etanercept [14] . It is typically administered via a subcutaneous injection of 25 mg twice a week for a period of 2 years. The most common side effect is pain at the site of injection. Anti-TNF therapy is not recommended for patients with active systemic infection. All patients are tested for latent tuberculosis by tuberculin skin testing or serum quantiferon testing. Serologic hepatitis B testing including antibody to hepatitis B core antigen (anti-HBc) and hepatitis B surface antigen (HBsAg) was done.
Patients with severe heart failure are excluded from using this therapy. A baseline CBC and liver function tests are done prior to therapy initiation and repeated at 4-6 week intervals. Sustained remission seems to occur less commonly after therapy cessation even after a period of 2 years.
Adalimumab
Adalimumab is a fully human immunoglobulin (Ig) G1 monoclonal anti-TNFa antibody. Toxoplasma and Candida and could make patients susceptible to reactivation with tuberculosis [42] . Infliximab has been associated anaphylactic reactions, demyelinating disease and heart failure and should be used with caution in patients with a known past medical history that may be affected by potential side effects [43] . The SITE cohort showed infliximab group to have a greater risk of cancer and overall mortality; however, it is proposed that TNF inhibitors do not initiate cancer but exacerbate pre-existing malignancies that are undetected [11, 14] . A study evaluating the effects of infliximab in patients with Behcet's disease uveoretinitis showed that it was well tolerated with no serious adverse effects occurring in about half of the patients. At the 1-year endpoint, the uveoretinitis had improved in 92% of patients. No flare-ups were seen during the 1 year period in 44% of patients and improvement in visual acuity was noted [44] .
Infliximab is administered as an intravenous infusion at 5 mg/kg at week 0 and 2 as loading doses followed by infusions at 4-week intervals.
For refractory cases, the doses can be as high as 10 mg/kg. The dosing can be increased or Daclizumab was not examined in the SITE cohort study; however, studies done on patients receiving it for transplants did not show an increased risk of malignancy or mortality [50] .
Unfortunately, daclizumab was withdrawn from the market in January 2010 due to its projected revenue when compared to alternative medications in the renal transplant field [11] .
Rituximab
Rituximab is a murine/human chimeric monoclonal IgG antibody against the CD20 antigen in B lymphocytes, thereby serving as a strong immune suppressant of the humoral arm of the immune system. The CD 20 marker is essential in B lymphocyte activation and differentiation [1] . It also inhibits T-cell activation through a reduction of antigen presentation by B cells and by inducing lysis of peripheral B lymphocytes. It has been employed in the therapy of lymphoma, leukemia, multiple myeloma, rheumatoid arthritis and uveitis [1] . Rituximab has been useful in treating chronic anterior uveitis refractive to steroids and other steroid agents [51] , inducing remission in a patient with relapsing necrotizing scleritis associated with granulomatosis with polyangiitis (Wegener's) (GPA) [52] , and inducing remission of retinal vasculitis in a patient with Behcet's disease [53] .
In MERSI, good results have been observed in inducing remission with rituximab in patients with refractory uveitis and treatment-resistant ocular cicatricial pemphigoid [1] .
Rituximab is administered as an intravenous infusion, 375 mg/m 2 , every week for 4 weeks. and was effective in causing a response rate of 92% with significant improvement in ocular inflammation and visual acuity [61, 62] .
Patients with multiple sclerosis-associated uveitis were treated with IFN-b 1a in case series and experienced improvements in ocular inflammation, macular edema and visual acuity [63] .
Side effects included fatigue, flu-like syndromes, mood changes such as depression and medication-induced SLE. IFNa 2a is given at dose of 3-6 million IU daily to three times a week [63] . Liver function tests, CBC and thyroid function tests are done prior to therapy initiation and then at 4-to 6-week intervals.
Treatment is continued with a goal of achieving inflammation control for 2 years prior to stopping therapy.
Tocilizumab
Tocilizumab is a humanized antibody to IL-6 which is an important cytokine involved in B and T cell activation and differentiation. It is currently approved for treatment of patients with moderate to severe rheumatoid arthritis or patients who have not had a favorable response to TNF-a agents [64, 65] 
Anakinra
Anakinra is an IL-1 receptor antagonist, IgG monoclonal antibody currently approved for rheumatoid arthritis [67] . IL-1 is a cytokine involved in the stimulation of inflammation and recruitment of inflammatory cells to a particular tissue [68] . A multi-center trial showed efficacy of Anakinra as first-line therapy for JIA [69] . It is administered as a subcutaneous injection 100 mg daily. Breastfeeding is contraindicated [2] .
Pregnancy and Uveitis Management
Azathioprine has been studied in pregnant renal transplant patients receiving azathioprine and prednisone and in pregnant patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. These studies showed no increase in pregnancy complications or congenital malformations.
Risks including lower gestational age, birth weight and prematurity have been reported [2, 10, 72, 73] . The fetal liver does not have the enzyme to convert azathioprine to its active form and may be protected from its effects. It may be used during pregnancy in situations of severe sight-threatening uveitis at daily dose not exceeding 2 mg/kg/day and breastfeeding is not recommended.
Methotrexate is also teratogenic and at elevated doses may have abortifacient properties and is contraindicated during pregnancy. Congenital anomalies include neural tube defects, limb, palate and growth retardation and cranial ossification [2, 10] .
Although methotrexate has not been shown to affect female fertility, there is a risk of sperm mutation in treated male patients. Therefore, it is recommended the methotrexate should be discontinued 4 months prior to conception.
Breastfeeding is also contraindicated [2, 10] . Mycophenolate mofetil has been shown to cross the placenta, but no data are available on teratogenic effects. It is contraindicated in pregnancy and during breast feeding. Due to its long half-life and hepatic circulation, it should be discontinued 6 weeks prior to conception.
Tacrolimus and cyclosporine cross the placenta. A recent study reviewing cyclosporine therapy during pregnancy concluded that the prevalence of major malformation in this group did not vary substantially with that of the general population [2, 74] . Both agents may be maintained in pregnancy at the lowest effective dose. Breast feeding is not recommended.
The use of biologic response modifiers such as etanercept, adalimumab and infliximab is growing, but there is limited experience on their use during pregnancy and breastfeeding.
As a result, these agents should be stopped once pregnancy is recognized [2] . Improved local drug delivery methods are also being advanced. Lee et al. [82] demonstrated the effectiveness of topical tacrolimus ointment in controlling refractory inflammatory ocular surface disease, such as scleritis and Mooren ulcer, and reducing inflammation recurrence and reliance on steroid use. For the intravitreal route, trials of micro-particle injectables are being conducted. These can be in the form of drug-eluting microparticles with sizes of 1-10 lm, suspended in a liquid carrier or microspheres with drugpolymer associations dispersed within a polymeric matrix [81] . 
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